Haemonetics (NYSE:HAE) Posts Earnings Results, Misses Expectations By $0.01 EPS

Haemonetics (NYSE:HAE) posted its quarterly earnings results on Thursday. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01), Zacks reports. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Haemonetics updated its FY 2025 guidance to 4.500-4.700 EPS.

Haemonetics Trading Down 11.6 %

Shares of Haemonetics stock traded down $8.29 on Thursday, reaching $62.95. 3,473,560 shares of the company’s stock were exchanged, compared to its average volume of 873,356. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. The company has a market capitalization of $3.16 billion, a P/E ratio of 26.12, a price-to-earnings-growth ratio of 1.07 and a beta of 0.39. The firm’s 50-day moving average is $77.44 and its two-hundred day moving average is $78.73. Haemonetics has a 52 week low of $61.43 and a 52 week high of $97.97.

Wall Street Analyst Weigh In

HAE has been the topic of several recent analyst reports. Barrington Research reiterated an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a research note on Wednesday, December 4th. JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research note on Friday, November 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $112.00 price objective on shares of Haemonetics in a research report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $108.78.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.